Description: I-FABP, Human, ELISA kit

Fatty acid-binding proteins (FABPs) are a class of cytoplasmic proteins that bind long chain fatty acids. FABPs are small intracellular proteins (~13-14 kDa) with a high degree of tissue specificity. They are abundantly present in various cell types and play an important role in the intracellular utilization of fatty acids, transport and metabolism. There are at least nine distinct types of FABP, each showing a specific pattern of tissue expression. Due to its small size, FABP leaks rapidly out of ischemically damaged necrotic cells leading to a rise in serum levels. Ischemically damaged tissues are characterized histologically by absence (or low presence) of FABP facilitating recognition of such areas. Intestinal FABP (I-FABP) is specifically localized in the epithelium cells of the small bowel. The I-FABP protein is derived from the human FABP2 gene. Normally, I-FABP is undetectable in serum. Many observations indicate that I-FABP is a useful biochemical marker for intestinal cell damage both in vivo and in vitro. Ischemically damaged cells are characterized histologically by absence (or low presence) of FABP facilitating recognition of areas of ischemically damaged cells.


Catalog number HK406-02
Product type Assays
Quantity 2 x 96 det.
Standard range 20 - 5,000 pg/ml
Detection level 20 pg/ml
Working volume 100 µl/well
Species Human
Application The human I-FABP ELISA kit is intended for the quantitative measure­ment of human I-FABP in cell culture medium, serum, plasma and urine. In serum or plasma samples, human I-FABP can be measured accurately if serum or plasma samples are diluted at least 2 times.
Disease Gastroenterology
Principle The human intestinal FABP ELISA is a ready-to-use solid-phase enzyme-linked immunosorbent assay based on the sandwich principle with a working time of 3˝ hours. The efficient format of a plate with twelve disposable 8-well strips allows free choice of batch size for the assay. Samples and standards are incubated in microtiter wells coated with antibo­dies recognizing human I-FABP Biotinylated tracer antibody will bind to captured human I-FABP. Streptavidin-peroxidase conjugate will bind to the biotinylated tracer antibody. Streptavidin-peroxidase conjugate will react with the substrate, tetramethylbenzidine (TMB). The enzyme reaction is stopped by the addition of citric acid. The absorbance at 450 nm is measured with a spectrophotometer. A standard curve is obtained by plotting the absorbance (linear) versus the corresponding concentrations of the human I-FABP standards (log). The human I-FABP concentration of samples, which are run concurrently with the standards, can be determined from the standard curve.
Storage and Stability Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
Precautions For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
References 1. Niewold, T et al; Plasma intestinal fatty acid binding protein (I-FABP) concentrations increase following intestinal ischemia in pigs. Res Vet Sci 2004, 77: 89
2. Morariu, A et al; Dexamethasone: benefit and prejudice for patients undergoing onpump coronary artery bypass grafting: a study on myocardial, pulmonary, renal, intestinal, and hepatic injury. Chest 2005, 128: 2677
3. Derikx, J et al; Detection of chemotherapy-induced enterocyte toxicity with circulating intestinal fatty acid binding protein. J Pediatr Hematol Oncol 2006, 28: 267
4. Cronk, D et al; Intestinal fatty acid binding protein (I-FABP) for the detection of strangulated mechanical small bowel obstruction. Curr Surg 2006, 63: 322
5. Derikx, P et al; Urine based detection of intestinal mucosal cell damage in neonates with suspected necrotising enterocolitis. Gut 2007, 56: 1473